{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:30:46Z","timestamp":1786480246346,"version":"build-2736575974"},"reference-count":114,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:p>Onconephrology is an upcoming and expanding subspecialty that deals with the intersections between hematology\/oncology and nephrology. With the paradigm shift in the understanding of cancer immunobiology and mechanisms of oncotherapeutic drug toxicities, it is important for a nephrologist to have a sound understanding of this field. Over the last 5 years, there have been immense developments in our understanding of kidney-related adverse events from various targeted, immuno- and cellular-based therapies. Pathogenic mechanisms of electrolyte imbalance, hypertension (oncohypertension), and AKI from multiple forms of cancer therapies have been explored. Significant research has also been conducted in the field of transplant onconephrology. In this review, we have tried to assimilate the most recent updates in the last 2 years in this ever-growing and fascinating field.<\/jats:p>","DOI":"10.34067\/kid.0001582022","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T18:00:16Z","timestamp":1670608816000},"page":"258-271","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Onconephrology 2022: An Update"],"prefix":"10.34067","volume":"4","author":[{"given":"Marco","family":"Bonilla","sequence":"first","affiliation":[{"name":"Section of Nephrology, Department of Medicine, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Gudsoorkar","sequence":"additional","affiliation":[{"name":"Division of Nephrology & Kidney Clinical Advancement, Research & Education (C.A.R.E.) Program, University of Cincinnati, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimda","family":"Wanchoo","sequence":"additional","affiliation":[{"name":"Glomerular Center at Northwell Health, Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Great Neck, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenar D.","family":"Jhaveri","sequence":"additional","affiliation":[{"name":"Glomerular Center at Northwell Health, Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Great Neck, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"2","key":"B1-20250823","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B2-20250823","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.xkme.2021.08.008","article-title":"Immune checkpoint inhibitors and kidney toxicity: advances in diagnosis and management","volume":"3","author":"Seethapathy","year":"2021","journal-title":"Kidney Med."},{"issue":"10","key":"B3-20250823","doi-asserted-by":"crossref","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer."},{"key":"B4-20250823","first-page":"sfac194","article-title":"The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis","author":"Kanbay","year":"2022","journal-title":"Clin Kidney J."},{"issue":"4","key":"B5-20250823","doi-asserted-by":"crossref","first-page":"e002292","DOI":"10.1136\/jitc-2020-002292","article-title":"Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study","volume":"9","author":"Lee","year":"2021","journal-title":"J Immunother Cancer."},{"issue":"9","key":"B6-20250823","doi-asserted-by":"crossref","first-page":"e005646","DOI":"10.1136\/jitc-2022-005646","article-title":"Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI","volume":"10","author":"Gupta","year":"2022","journal-title":"J Immunother Cancer."},{"issue":"22","key":"B7-20250823","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med."},{"issue":"4","key":"B8-20250823","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.kint.2022.07.019","article-title":"Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer","volume":"102","author":"Gupta","year":"2022","journal-title":"Kidney Int."},{"issue":"9","key":"B9-20250823","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/ckj\/sfab090","article-title":"Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review","volume":"14","author":"Kitchlu","year":"2021","journal-title":"Clin Kidney J."},{"issue":"5","key":"B10-20250823","doi-asserted-by":"crossref","first-page":"399","DOI":"10.34067\/KID.0000422020","article-title":"Use of immune checkpoint inhibitors in end stage kidney disease patients, single center experience and review of the literature","volume":"1","author":"Hirsch","year":"2020","journal-title":"Kidney360."},{"issue":"7","key":"B11-20250823","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet."},{"issue":"4","key":"B12-20250823","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events","volume":"6","author":"Isik","year":"2021","journal-title":"Kidney Int Rep."},{"key":"B13-20250823","article-title":"Soluble and cell-based markers of immune checkpoint inhibitor associated nephritis","author":"Sise","year":"2022","journal-title":"bioRxiv."},{"key":"B14-20250823","article-title":"Cytokines and immune cell phenotype in acute kidney injury associated with immune checkpoint inhibitors","author":"Farooqui","year":"2022","journal-title":"Kidney Int Rep."},{"issue":"1","key":"B16-20250823","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2021.04.009","article-title":"Capmatinib-induced pseudo-acute kidney injury: a case report","volume":"79","author":"Mohan","year":"2022","journal-title":"Am J Kidney Dis."},{"issue":"5","key":"B17-20250823","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/cpt.1296","article-title":"Abemaciclib inhibits renal tubular secretion without changing glomerular filtration rate","volume":"105","author":"Chappell","year":"2019","journal-title":"Clin Pharmacol Ther."},{"issue":"2","key":"B18-20250823","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00228-020-03070-0","article-title":"A real or apparent decrease in glomerular filtration rate in patients using olaparib?","volume":"77","author":"Bruin","year":"2020","journal-title":"Eur J Clin Pharmacol."},{"issue":"1","key":"B19-20250823","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/ijgc-2019-000714","article-title":"Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors","volume":"30","author":"Zibetti","year":"2020","journal-title":"Int J Gynecol Cancer."},{"issue":"25","key":"B20-20250823","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in combination with Fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol."},{"issue":"1","key":"B21-20250823","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of Abemaciclib plus Fulvestrant on overall survival in hormone receptor\u2013positive, ERBB2-negative breast cancer that progressed on endocrine therapy\u2014MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol."},{"issue":"3","key":"B22-20250823","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ekir.2021.11.033","article-title":"Clinicopathologic features of acute kidney injury associated with CDK4\/6 inhibitors","volume":"7","author":"Gupta","year":"2021","journal-title":"Kidney Int Rep."},{"issue":"1-2","key":"B23-20250823","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/23993693221085285","article-title":"Ribociclib-induced pseudo-acute kidney injury","volume":"6","author":"Sy-Go","year":"2022","journal-title":"J Onco-Nephrol."},{"issue":"6","key":"B24-20250823","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.kint.2021.08.022","article-title":"Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition","volume":"100","author":"Bai","year":"2021","journal-title":"Kidney Int."},{"issue":"5","key":"B25-20250823","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1021\/acschembio.5b01063","article-title":"Chemical proteomics reveals ferrochelatase as a common off target of kinase inhibitors","volume":"11","author":"Klaeger","year":"2016","journal-title":"ACS Chem Biol."},{"issue":"1","key":"B26-20250823","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1172\/JCI1347","article-title":"Molecular defects in ferrochelatase in patients with protoporphyria requiring liver transplantation","volume":"102","author":"Bloomer","year":"1998","journal-title":"J Clin Invest."},{"issue":"6","key":"B27-20250823","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.kint.2022.07.024","article-title":"Hemopexin accumulates in kidneys and worsens acute kidney injury by causing hemoglobin deposition and exacerbation of iron toxicity in proximal tubules","volume":"102","author":"Fan","year":"2022","journal-title":"Kidney Int."},{"issue":"6","key":"B28-20250823","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2215\/CJN.14671121","article-title":"Electrolyte and acid-base disorders associated with cancer immunotherapy","volume":"17","author":"Uppal","year":"2022","journal-title":"Clin J Am Soc Nephrol."},{"issue":"9","key":"B29-20250823","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/ndt\/gfaa326","article-title":"Immune checkpoint inhibitor\u2013associated hypercalcaemia","volume":"37","author":"Izzedine","year":"2020","journal-title":"Nephrol Dial Transpl."},{"issue":"4","key":"B30-20250823","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.kint.2021.06.001","article-title":"Immune checkpoint inhibitor-associated electrolyte disorders: query of the food and drug administration adverse event reporting system","volume":"100","author":"Wanchoo","year":"2021","journal-title":"Kidney Int."},{"issue":"6","key":"B31-20250823","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1681\/ASN.2021070997","article-title":"Tumor lysis syndrome and AKI: beyond crystal mechanisms","volume":"33","author":"Arnaud","year":"2022","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"B32-20250823","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/ckj\/sfy026","article-title":"Renal involvement in chronic lymphocytic leukemia","volume":"11","author":"Wanchoo","year":"2018","journal-title":"Clin Kidney J."},{"issue":"20","key":"B34-20250823","article-title":"Selinexor for refractory multiple myeloma","volume":"381","author":"Jhaveri","year":"2019","journal-title":"N Engl J Med."},{"issue":"9","key":"B35-20250823","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1038\/s41375-020-0756-6","article-title":"Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials","volume":"34","author":"Gavriatopoulou","year":"2020","journal-title":"Leukemia."},{"issue":"3","key":"B36-20250823","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2020.06.007","article-title":"Selinexor-associated hyponatremia: single-center, real-world data","volume":"98","author":"Kala","year":"2020","journal-title":"Kidney Int."},{"issue":"7","key":"B37-20250823","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.mayocp.2022.05.018","article-title":"Incidence and risk factors for acute kidney injury after Chimeric antigen receptor T-cell therapy","volume":"97","author":"Farooqui","year":"2022","journal-title":"Mayo Clin Proc."},{"issue":"12","key":"B38-20250823","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1093\/ndt\/gfaa272","article-title":"Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors","volume":"36","author":"Seethapathy","year":"2021","journal-title":"Nephrol Dial Transpl."},{"issue":"1","key":"B39-20250823","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute kidney injury and electrolyte abnormalities after Chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am J Kidney Dis."},{"issue":"10","key":"B40-20250823","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2215\/CJN.02780312","article-title":"Onco-nephrology: renal toxicities of chemotherapeutic agents","volume":"7","author":"Perazella","year":"2012","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"B41-20250823","doi-asserted-by":"crossref","first-page":"154","DOI":"10.34067\/KID.0005622020","article-title":"Hypomagnesemia in the cancer patient","volume":"2","author":"Workeneh","year":"2021","journal-title":"Kidney360."},{"issue":"3","key":"B42-20250823","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.xkme.2020.01.010","article-title":"SGLT2 inhibitors for treatment of refractory hypomagnesemia: a case report of 3 patients","volume":"2","author":"Ray","year":"2020","journal-title":"Kidney Med."},{"issue":"10","key":"B43-20250823","doi-asserted-by":"crossref","first-page":"100533","DOI":"10.1016\/j.xkme.2022.100533","article-title":"SodiumGlucose Cotransporter 2 inhibitors and management of refractory hypomagnesemia without Overt urinary magnesium wasting: a report of 2 cases","volume":"4","author":"Shah","year":"2022","journal-title":"Kidney Med."},{"issue":"12","key":"B44-20250823","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1007\/s00125-016-4101-6","article-title":"Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials","volume":"59","author":"Tang","year":"2016","journal-title":"Diabetologia."},{"issue":"5","key":"B45-20250823","doi-asserted-by":"crossref","first-page":"F1224","DOI":"10.1152\/ajprenal.00370.2019","article-title":"Renal SGLT mRNA expression in human health and disease: a study in two cohorts","volume":"317","author":"Srinivasan Sridhar","year":"2019","journal-title":"Am J Physiol Ren Physiol."},{"issue":"5","key":"B46-20250823","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.ackd.2021.09.011","article-title":"Onco-hypertension: an emerging specialty","volume":"28","author":"Gudsoorkar","year":"2021","journal-title":"Adv Chronic Kidney Dis."},{"issue":"11","key":"B48-20250823","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/annonc\/mdv369","article-title":"Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors","volume":"26","author":"Boer","year":"2015","journal-title":"Ann Oncol."},{"issue":"6","key":"B49-20250823","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","article-title":"Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events","volume":"12","author":"Touyz","year":"2018","journal-title":"J Am Soc Hypertens."},{"issue":"7","key":"B50-20250823","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCRESAHA.121.318051","article-title":"Hypertension and prohypertensive antineoplastic therapies in cancer patients","volume":"128","author":"van Dorst","year":"2021","journal-title":"Circ Res."},{"issue":"4","key":"B51-20250823","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11912-012-0242-z","article-title":"VEGF inhibition, hypertension, and renal toxicity","volume":"14","author":"Hayman","year":"2012","journal-title":"Curr Oncol Rep."},{"key":"B52-20250823","article-title":"How I manage hypertension and proteinuria associated with VEGF inhibitor","author":"Rashidi","year":"2022","journal-title":"Clin J Am Soc Nephrol."},{"issue":"2","key":"B53-20250823","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1681\/ASN.2018080853","article-title":"Therapeutic inhibition of VEGF signaling and associated nephrotoxicities","volume":"30","author":"Estrada","year":"2019","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B54-20250823","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nrneph.2015.15","article-title":"Renal effects of targeted anticancer therapies","volume":"11","author":"Porta","year":"2015","journal-title":"Nat Rev Nephrol."},{"issue":"1","key":"B55-20250823","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12020-017-1233-5","article-title":"Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes","volume":"56","author":"Haddad","year":"2017","journal-title":"Endocrine."},{"issue":"6","key":"B56-20250823","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41416-018-0164-0","article-title":"Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma","volume":"119","author":"Powles","year":"2018","journal-title":"Br J Cancer."},{"issue":"2","key":"B57-20250823","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamaoncol.2021.6268","article-title":"Apatinib vs placebo in patients with locally advanced or metastatic, radioactive iodine\u2013refractory differentiated thyroid cancer","volume":"8","author":"Lin","year":"2022","journal-title":"JAMA Oncol."},{"issue":"2","key":"B58-20250823","doi-asserted-by":"crossref","first-page":"e0211228","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis","volume":"14","author":"Caldeira","year":"2019","journal-title":"PLoS One."},{"issue":"12","key":"B59-20250823","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","article-title":"Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies","volume":"3","author":"Coutre","year":"2019","journal-title":"Blood Adv."},{"issue":"26","key":"B60-20250823","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med."},{"issue":"22","key":"B61-20250823","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood."},{"issue":"4","key":"B62-20250823","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med."},{"issue":"7","key":"B63-20250823","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.3390\/ijms22073464","article-title":"PI3K inhibitors in cancer: clinical implications and adverse effects","volume":"22","author":"Mishra","year":"2021","journal-title":"Int J Mol Sci."},{"issue":"35","key":"B64-20250823","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by Copanlisib in relapsed or refractory Indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol."},{"issue":"3","key":"B65-20250823","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.clml.2018.11.021","article-title":"Optimal management of adverse events from Copanlisib in the treatment of patients with non-Hodgkin lymphomas","volume":"19","author":"Cheson","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"44","key":"B66-20250823","doi-asserted-by":"crossref","first-page":"16296","DOI":"10.1073\/pnas.0607899103","article-title":"The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation","volume":"103","author":"Zhao","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"suppl_10","key":"B67-20250823","doi-asserted-by":"crossref","first-page":"x21","DOI":"10.1093\/annonc\/mdz440","article-title":"Management of toxicity to isoform \u03b1-specific PI3K inhibitors","volume":"30","author":"Nunnery","year":"2019","journal-title":"Ann Oncol."},{"key":"B68-20250823","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1161\/HYPERTENSIONAHA.122.19865","article-title":"Immune checkpoint inhibitors do not increase short-term risk of hypertension in cancer patients: a systematic literature review and meta-analysis","volume":"79","author":"Minegishi","year":"2022","journal-title":"Hypertension."},{"issue":"8","key":"B69-20250823","doi-asserted-by":"crossref","first-page":"e198890","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis","volume":"2","author":"Mincu","year":"2019","journal-title":"JAMA Netw Open."},{"issue":"4","key":"B70-20250823","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","article-title":"Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial","volume":"32","author":"Wu","year":"2021","journal-title":"Ann Oncol."},{"issue":"17","key":"B71-20250823","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1158\/1078-0432.CCR-18-0042","article-title":"FDA approval summary: niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy","volume":"24","author":"Ison","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"3","key":"B72-20250823","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","article-title":"The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer","volume":"16","author":"Iacovelli","year":"2018","journal-title":"Clin Genitourin Cancer."},{"issue":"2","key":"B73-20250823","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10549-016-3761-8","article-title":"Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27","volume":"156","author":"Chapman","year":"2016","journal-title":"Breast Cancer Res Treat."},{"issue":"5","key":"B74-20250823","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1681\/ASN.2018090941","article-title":"Thrombospondin type 1 domain\u2013containing 7A localizes to the slit diaphragm and stabilizes membrane dynamics of fully differentiated podocytes","volume":"30","author":"Herwig","year":"2019","journal-title":"J Am Soc Nephrol."},{"issue":"24","key":"B75-20250823","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med."},{"issue":"1","key":"B77-20250823","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int."},{"issue":"4","key":"B78-20250823","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.kint.2020.07.039","article-title":"NELL1 is a target antigen in malignancy-associated membranous nephropathy","volume":"99","author":"Caza","year":"2021","journal-title":"Kidney Int."},{"issue":"5","key":"B79-20250823","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1681\/ASN.2020081165","article-title":"Protocadherin 7-associated membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B80-20250823","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A systematic review of immune checkpoint inhibitor-associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Rep."},{"issue":"10","key":"B81-20250823","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1016\/j.ekir.2021.08.021","article-title":"Minimal change disease associated with Durvalumab","volume":"6","author":"Toda","year":"2021","journal-title":"Kidney Int Rep."},{"issue":"1","key":"B82-20250823","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/23993693211004612","article-title":"Phospholipase A2 receptor antibody mediated membranous nephropathy associated with cemiplimab","volume":"5","author":"Bonilla","year":"2021","journal-title":"J Onco-Nephrol."},{"issue":"1-2","key":"B83-20250823","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/23993693211064627","article-title":"A case of immune-complex mediated glomerulonephritis associated with pembrolizumab","volume":"6","author":"Bonilla","year":"2022","journal-title":"J Onco-Nephrol"},{"issue":"2","key":"B84-20250823","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.ackd.2021.11.003","article-title":"Kidney disease following hematopoietic stem cell transplantation","volume":"29","author":"Abudayyeh","year":"2022","journal-title":"Adv Chronic Kidney Dis."},{"issue":"6","key":"B85-20250823","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bbmt.2014.03.003","article-title":"Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning","volume":"20","author":"Raj","year":"2014","journal-title":"Biol Blood Marrow Transplant."},{"issue":"9","key":"B86-20250823","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1038\/s41409-022-01720-8","article-title":"Acute kidney injury caused by haplostorm after allogenic hematopoietic stem cell transplant","volume":"57","author":"Hanna","year":"2022","journal-title":"Bone Marrow Transplant."},{"issue":"12","key":"B87-20250823","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/j.bbmt.2019.07.027","article-title":"Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation","volume":"25","author":"Imus","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"B88-20250823","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2215\/CJN.00380705","article-title":"Nephrotic syndrome after hematopoietic cell transplantation: do glomerular lesions represent renal graft-versus-host disease?","volume":"1","author":"Brukamp","year":"2006","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"B89-20250823","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.kint.2020.12.005","article-title":"The case | proteinuria in a patient with hematopoietic stem cell transplantation","volume":"99","author":"Hiramatsu","year":"2021","journal-title":"Kidney Int."},{"issue":"1","key":"B90-20250823","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/MAJ.0b013e318267b5cd","article-title":"Detection of anti-PLA2R autoantibodies and IgG subclasses in post-allogeneic hematopoietic stem cell transplantation membranous nephropathy","volume":"346","author":"Huang","year":"2013","journal-title":"Am J Med Sci."},{"issue":"6","key":"B91-20250823","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/j.ajkd.2021.07.021","article-title":"Membranous nephropathy with extensive tubular basement membrane deposits following allogeneic hematopoietic cell transplant: a report of 5 cases","volume":"79","author":"Nasr","year":"2022","journal-title":"Am J Kidney Dis."},{"issue":"7","key":"B92-20250823","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.ekir.2021.04.033","article-title":"NELL1-associated membranous glomerulopathy after hematopoietic stem cell transplantation","volume":"6","author":"Kudose","year":"2021","journal-title":"Kidney Int Rep."},{"issue":"5","key":"B93-20250823","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1681\/ASN.2021111488","article-title":"Hematopoietic stem cell transplant-membranous nephropathy is associated with protocadherin FAT1","volume":"33","author":"Sethi","year":"2022","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B94-20250823","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/med.21286","article-title":"Sleeping giants: emerging roles for the fat cadherins in health and disease","volume":"34","author":"Sadeqzadeh","year":"2014","journal-title":"Med Res Rev."},{"key":"B95-20250823","doi-asserted-by":"crossref","first-page":"10822","DOI":"10.1038\/ncomms10822","article-title":"FAT1 mutations cause a glomerulotubular nephropathy","volume":"7","author":"Gee","year":"2016","journal-title":"Nat Commun."},{"issue":"21","key":"B96-20250823","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra2101920","article-title":"Somatic mutations in \u201cBenign\u201d disease","volume":"384","author":"Lenormand","year":"2021","journal-title":"N Engl J Med."},{"issue":"3","key":"B97-20250823","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41408-020-0295-4","article-title":"Serum free light chain level at diagnosis in myeloma cast nephropathy\u2014a multicentre study","volume":"10","author":"Yadav","year":"2020","journal-title":"Blood Cancer J."},{"issue":"12","key":"B98-20250823","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"3","key":"B99-20250823","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1053\/j.ajkd.2021.12.014","article-title":"Complement activation and thrombotic microangiopathy associated with monoclonal Gammopathy: a National French case series","volume":"80","author":"Martins","year":"2022","journal-title":"Am J Kidney Dis."},{"issue":"4","key":"B100-20250823","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2215\/CJN.12890921","article-title":"Kidney histopathologic spectrum and clinical indicators associated with MGRS","volume":"17","author":"Yong","year":"2022","journal-title":"Clin J Am Soc Nephrol."},{"issue":"23","key":"B101-20250823","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.20.00298","article-title":"Randomized trial comparing double versus triple bortezomib-based regimen in patients with multiple myeloma and acute kidney injury due to cast nephropathy","volume":"38","author":"Bridoux","year":"2020","journal-title":"J Clin Oncol."},{"issue":"1","key":"B102-20250823","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.kint.2018.02.020","article-title":"A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits","volume":"94","author":"Gumber","year":"2018","journal-title":"Kidney Int."},{"issue":"19","key":"B103-20250823","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood."},{"issue":"4","key":"B104-20250823","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ekir.2020.01.011","article-title":"The role of kidney transplantation in monoclonal Ig deposition disease","volume":"5","author":"Angel-Korman","year":"2020","journal-title":"Kidney Int Rep."},{"issue":"5","key":"B105-20250823","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1681\/ASN.2020101541","article-title":"Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits","volume":"32","author":"Zand","year":"2021","journal-title":"J Am Soc Nephrol."},{"issue":"12","key":"B106-20250823","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/14728222.2017.1398235","article-title":"Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis","volume":"21","author":"Nuvolone","year":"2017","journal-title":"Expert Opin Ther Targets."},{"issue":"1","key":"B107-20250823","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med."},{"issue":"11","key":"B108-20250823","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-143-11-200512060-00005","article-title":"Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial","volume":"143","author":"Clark","year":"2005","journal-title":"Ann Intern Med."},{"issue":"21","key":"B109-20250823","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2017.17924","article-title":"Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial","volume":"318","author":"Bridoux","year":"2017","journal-title":"JAMA."},{"issue":"4","key":"B110-20250823","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(19)30014-6","article-title":"High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial","volume":"6","author":"Hutchison","year":"2019","journal-title":"Lancet Haematol."},{"issue":"2","key":"B111-20250823","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1053\/j.ackd.2021.09.002","article-title":"Transplant onconephrology in patients with kidney transplants","volume":"29","author":"Murakami","year":"2022","journal-title":"Adv Chronic Kidney Dis."},{"issue":"1","key":"B112-20250823","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int."},{"issue":"8","key":"B113-20250823","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study","volume":"23","author":"Carroll","year":"2022","journal-title":"Lancet Oncol."},{"issue":"2","key":"B114-20250823","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1056\/NEJMc1614298","article-title":"Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab","volume":"376","author":"Barnett","year":"2017","journal-title":"N Engl J Med."},{"issue":"3","key":"B115-20250823","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2215\/CJN.06290615","article-title":"Trends in survival and renal recovery in patients with multiple myeloma or light-chain amyloidosis on chronic dialysis","volume":"11","author":"Decourt","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"issue":"9","key":"B116-20250823","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/ndt\/gfaa361","article-title":"Kidney transplantation in patients with multiple myeloma: narrative analysis and review of the last 2 decades","volume":"37","author":"Chitty","year":"2022","journal-title":"Nephrol Dial Transplant."},{"issue":"12","key":"B117-20250823","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/ndt\/gfac196","article-title":"Outcomes of kidney transplantation in patients with myeloma and amyloidosis in the US","volume":"37","author":"Ng","year":"2022","journal-title":"Nephrol Dial Transplant."},{"issue":"8","key":"B118-20250823","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-022-00714-5","article-title":"Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through the International Kidney and Monoclonal Gammopathy Research Group","volume":"12","author":"Havasi","year":"2022","journal-title":"Blood Cancer J."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0001582022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:00:08Z","timestamp":1786478408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0001582022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0001582022","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,9]]},"assertion":[{"value":"2022-09-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}